ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.
You may also be interested in...
Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.
US FDA’s monthly refuse-to-receive numbers for ANDAs are down early in FY 2017, suggesting that sponsor have an increased understanding of the agency’s standards.
Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.